canada semaglutide patent expiry Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Aspen Pharmacare wins Canada approval

They might suggest additional testing, alternative medications, or lifestyle changes before beginning a GLP-1 medication

The effects just operate on a fundamentally different scale than pharmaceutical interventions

Mechanism & Research Background GLP-3 (RT) (LY3437943) is a 39-amino acid synthetic peptide engineered as a triple-receptor agonist with concurrent activity at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)

The report combines genetic knowledge with personalised guidance on diet, exercise, supplements, and lifestyle

However, as compared to Old Con females, age-matched L2-Cmu-treated females had ~50% greater exercise tolerance (Fig